Patent Confirmation Assignment
Exhibit 6.2
Patent Confirmation Assignment
This patent confirmation assignment (the “Assignment”) is entered into by and between:
| (1) | The bankruptcy estate of XNK Therapeutics AB (publ), reg. no. 556894-6601, c/o Advokatfirma DLA Piper Sweden KB Box 7315, 103 90 Stockholm, Sweden (the “Bankruptcy Estate”); and |
| (2) | NÖK Therapeutics Inc., a company incorporated and registered in the United States of America, ▇▇▇▇ ▇. ▇▇ ▇▇▇. ▇, ▇▇▇▇▇ ▇▇▇, ▇▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇ (the “Buyer”). |
The above parties are hereinafter jointly referred to as the “Parties” and each individually as a “Party”.
BACKGROUND
| (a) | XNK Therapeutics AB, reg. no. 556894-6601, (the “Company”), a limited liability company construed under the laws of Sweden, was declared bankrupt on 9 April 2024, and certain parts of the Company’s assets were subsequently sold by the Bankruptcy Estate to the Buyer under patent transfer and assignment agreement (the “Agreement”), dated 23 May 2024 (the “Effective Date”). |
| (b) | As part of the Agreement, the terms of which are otherwise confidential, it was agreed that the patents listed in Schedule 1 (the “Patents”) should be assigned and transferred to the Buyer, including all right, titles and interests to the Patents. |
| (c) | The Parties are therefore executing this Assignment in order to confirm and record the transfer of the Patents from the Bankruptcy Estate to the Buyer with the relevant patent offices. |
In light of the above, the Parties confirm and agree the following.
| 1. | ASSIGNMENT |
Pursuant to and for the consideration set out in the Agreement, the Bankruptcy Estate hereby confirms that, with effect from the Effective Date, it has assigned and transferred to the Buyer, which the Buyer has accepted, the Patents, including, without limitation, the absolute right, titles and interests in and to the Patents, and in and to all and any inventions disclosed in the Patents.
| 2. | FURTHER ASSURANCE |
Each Party shall, and shall use all reasonable endeavours to procure that any necessary third party shall, promptly execute and deliver such documents and perform such acts as may be required for the purpose of giving full effect to this Assignment.
| 3. | RELATIONSHIP TO THE HEAD AGREEMENT |
This Assignment is entered into for confirmatory and recording purposes and any and all provisions of the Agreement remain in full force and effect.
[Signature page to follow]
| DLA Piper | 1 |
The Assignment has been executed in one (1) or multiple copies and signed digitally. Each such signed copy shall be deemed an original and all of which together shall constitute one and the same Assignment, of which each Party shall receive a PDF copy.
|
Bankruptcy Estate |
NÖK Therapeutics Inc. | |
| /s/ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇ | /s/ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ | |
| ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇ | ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ |
| DLA Piper | 2 |
Schedule 1
“Patents”
|
Title: Expansion of NK Cells Applicant/Owner: Cellprotect Nordic Pharmaceuticals AB | ||||||||||||||
| Country | Inventor(s) | Appl. No. | Appl. Date | Reg. no. | Reg. date | Renewal Date | Status | |||||||
| Belgium | Evren Alici | EP10756430 | 25 Mar 2010 | EP2411507 | 25 Sept 2019 | 25 Mar 2025 | Granted | |||||||
| Czech Republic | Evren Alici | EP10756430 | 25 Mar 2010 | EP2411507 | 25 Sept 2019 | 25 Mar 2025 | Granted | |||||||
| Denmark | Evren Alici | EP10756430 | 25 Mar 2010 | EP2411507 | 25 Sept 2019 | 25 Mar 2025 | Granted | |||||||
| Finland | Evren Alici | EP10756430 | 25 Mar 2010 | EP2411507 | 25 Sept 2019 | 25 Mar 2025 | Granted | |||||||
| France | Evren Alici | EP10756430 | 25 Mar 2010 | EP2411507 | 25 Sept 2019 | 25 Mar 2025 | Granted | |||||||
| Germany | Evren Alici | EP10756430 | 25 Mar 2010 | EP2411507 | 25 Sept 2019 | 25 Mar 2025 | Granted | |||||||
| Ireland | Evren Alici | EP10756430 | 25 Mar 2010 | EP2411507 | 25 Sept 2019 | 25 Mar 2025 | Granted | |||||||
| Italy | Evren Alici | EP10756430 | 25 Mar 2010 | EP2411507 | 25 Sept 2019 | 25 Mar 2025 | Granted | |||||||
| ▇▇▇▇▇▇▇▇▇ | ▇▇▇▇▇ Alici | EP10756430 | 25 Mar 2010 | EP2411507 | 25 Sept 2019 | 25 Mar 2025 | Granted | |||||||
| the Netherlands | Evren Alici | EP10756430 | 25 Mar 2010 | EP2411507 | 25 Sept 2019 | 25 Mar 2025 | Granted | |||||||
| Norway | Evren Alici | EP10756430 | 25 Mar 2010 | EP2411507 | 25 Sept 2019 | 25 Mar 2025 | Granted | |||||||
| Poland | Evren Alici | EP10756430 | 25 Mar 2010 | EP2411507 | 25 Sept 2019 | 25 Mar 2025 | Granted | |||||||
| Portugal | Evren Alici | EP10756430 | 25 Mar 2010 | EP2411507 | 25 Sept 2019 | 25 Mar 2025 | Granted | |||||||
| Spain | Evren Alici | EP10756430 | 25 Mar 2010 | EP2411507 | 25 Sept 2019 | 25 Mar 2025 | Granted | |||||||
| Sweden | Evren Alici | EP10756430 | 25 Mar 2010 | EP2411507 | 25 Sept 2019 | 25 Mar 2025 | Granted | |||||||
| Switzerland | Evren Alici | EP10756430 | 25 Mar 2010 | EP2411507 | 25 Sept 2019 | 25 Mar 2025 | Granted | |||||||
| Turkey | Evren Alici | EP10756430 | 25 Mar 2010 | EP2411507 | 25 Sept 2019 | 25 Mar 2025 | Granted | |||||||
| UK | Evren Alici | EP10756430 | 25 Mar 2010 | EP2411507 | 25 Sept 2019 | 25 Mar 2025 | Granted | |||||||
| [Intentionally left blank] | ||||||||||||||
| China | Evren Alici | CN 201080021237.8 | 2010-03-25 | CN 102428173 | Granted | |||||||||
| Hong Kong | ▇▇▇▇▇ ▇▇▇▇▇ | HK 12110647.2 | 2010-03-25 | HK 1170258 | 20 Mar 2015 | 25 Mar 2025 | Granted | |||||||
| Japan | Evren Alici | JP 2017-208238 | 2010-03-25 | JP 2018-046840 | 25 Mar 2025 | Granted | ||||||||
| Republic of Korea | ▇▇▇▇▇ ▇▇▇▇▇ | KR ▇▇-▇▇▇▇-▇▇▇▇▇▇▇ | 2010-03-25 | 1018815200000 | 18 July 2018 | 5 July 2024 | Granted | |||||||
| USA | Evren Alici | US 13/260,004 | 25 Mar 2010 | US 8,877,182 | 4 Nov 2014 | 25 Mar 2026 | Granted | |||||||
| DLA Piper | 3 |
|
Title: Expanded NK Cells Applicant/owner: Cellprotect Nordic Pharmaceuticals AB | ||||||||||||||
| Country | Inventor(s) | Appl. No. | Appl. Date | Reg. no. | Reg. date | Renewal Date | Status | |||||||
| USA | Sirac Dilber, Evren Alici | US 14/830,758 | 20 Aug 2015 | US 9,585,914 | 7 March 2017 |
1 maint. fee paid 2020 2 maint. fee to be paid 7-7,5 years after issue date |
Granted | |||||||
|
Title: Medical Uses Applicant/owner: XNK Therapeutics AB | ||||||||||||||
| Country | Inventor(s) | Appl. No. | Appl. Date | Reg. no. | Reg. date | Renewal Date | Status | |||||||
| China |
▇▇▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇▇ ▇▇▇▇, ▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇, ▇▇▇▇-▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ |
CN 201980029357.3 | 30 April 2019 | Pending | ||||||||||
| EP |
▇▇▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇▇ ▇▇▇▇, ▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇, ▇▇▇▇-▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ |
EP 3787685 | 30 April 2019 | Pending | ||||||||||
| Hong Kong |
▇▇▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇▇ ▇▇▇▇, ▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇, ▇▇▇▇-▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ |
62021036993.5 | 30 April 2019 | Pending | ||||||||||
| Hong Kong |
▇▇▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇▇ ▇▇▇▇, ▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇, ▇▇▇▇-▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ |
62021038634.3 | 30 April 2019 | Pending | ||||||||||
| Japan |
▇▇▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇▇ ▇▇▇▇, ▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇, ▇▇▇▇-▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ |
JP 2021-510533 | 30 April 2019 | Pending | ||||||||||
| Republic of Korea |
▇▇▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇▇ ▇▇▇▇, ▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇, ▇▇▇▇-▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ |
KR ▇▇-▇▇▇▇-▇▇▇▇▇▇▇ |
30 April 2019 | Pending | ||||||||||
| US |
▇▇▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇▇ ▇▇▇▇, ▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇, ▇▇▇▇-▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ |
17/04,8702 | 30 April 2019 | Pending | ||||||||||
|
Title: Methods Applicant/owner: XNK Therapeutics AB | ||||||||||||||
| Country | Inventor(s) | Appl. No. | Appl. Date | Reg. no. | Reg. date | Renewal Date | Status | |||||||
| PCT | ▇▇▇ ▇▇▇-▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ | PCT/GB2022/079547 | 24 Oct 2022 | N/A | N/A | N/A | EP and USA has been designated. | |||||||
| DLA Piper | 4 |